Abstract
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) developed consensus statements on pre-invasive vulvar lesions in order to improve the quality of care for patients with vulvar squamous intraepithelial neoplasia, vulvar Paget disease in situ, and melanoma in situ. For differentiated vulvar intraepithelial neoplasia (dVIN), an excisional procedure must always be adopted. For vulvar high-grade squamous intraepithelial lesion (VHSIL), both excisional procedures and ablative ones can be used. The latter can be considered for anatomy and function preservation and must be preceded by several representative biopsies to exclude malignancy. Medical treatment (imiquimod or cidofovir) can be considered for VHSIL. Recent studies favor an approach of using imiquimod in vulvar Paget’s disease. Surgery must take into consideration that the extension of the disease is usually wider than what is evident in the skin. A 2 cm margin is usually considered necessary. A wide local excision with 1 cm free surgical margins is recommended for melanoma in situ. Following treatment of pre-invasive vulvar lesions, women should be seen on a regular basis for careful clinical assessment, including biopsy of any suspicious area. Follow-up should be modulated according to the risk of recurrence (type of lesion, patient age and immunological conditions, other associated lower genital tract lesions).
Original language | English |
---|---|
Pages (from-to) | 830-845 |
Number of pages | 17 |
Journal | International Journal of Gynecological Cancer |
Volume | 32 |
Issue number | 7 |
Early online date | 21 Jun 2022 |
DOIs | |
Publication status | Published - 4 Jul 2022 |
Event | 22nd European Gynaecological Oncology Congress of the European Society of Gynaecological Oncology - Prague, Prague, Czech Republic Duration: 23 Oct 2021 → 25 Oct 2022 https://esgo.org/esgo2021/#:~:text=Europe's%20Leading%20Gynaecological%20Oncology%20Gathering,Prague%2C%20Czech%20Republic%20%2B%20Online. |
Bibliographical note
FundingAll costs relating to the development process were covered by ESGO, ISSVD, ECSVD, and EFC funds.
Data Availability Statement
Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/ijgc-2021-003262).Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise